Neurotrophic Effects of Intermittent Fasting, Calorie Restriction and Exercise: A Review and Annotated Bibliography [PDF]
arXiv, 2023 In the last decades, important progress has been achieved in the understanding of the neurotrophic effects of intermittent fasting (IF), caloric restriction (CR) and exercise. Improved neuroprotection, synaptic plasticity and adult neurogenesis (NSPAN) are essential examples of these neurotrophic effects. The importance in this respect of the metabolic
arxiv
Bridging the Gap Between Diabetes and Stroke in Search of High Clinical Relevance Therapeutic Targets [PDF]
, 2020 Diabetes affects more than 425 million people worldwide, a scale approaching pandemic proportion. Diabetes represents a major risk factor for stroke, and therefore is actively addressed for stroke prevention. However, how diabetes affects stroke severity has not yet been extensively considered, which is surprising given the evident but understudied ...
arxiv +1 more source
Gavestinel does not improve outcome after acute intracerebral hemorrhage: an analysis from the GAIN International and GAIN Americas studies [PDF]
, 2005 <p><b>Background and Purpose:</b> Glycine Antagonist in Neuroprotection (GAIN) International and GAIN Americas trials were prospectively designed, randomized, placebo-controlled trials of gavestinel, a glycine-site antagonist and ...
Brown, D.L. +9 more
core +1 more source
Mechanism of neuroprotection by trehalose: controversy surrounding autophagy induction
Cell Death and Disease, 2018 Trehalose is a non-reducing disaccharide with two glucose molecules linked through an α, α-1,1-glucosidic bond. Trehalose has received attention for the past few decades for its role in neuroprotection especially in animal models of various ...
He‐Jin Lee, Y. Yoon, Seung-Jae Lee
semanticscholar +1 more source
Mitochondria and neuroprotection in stroke: Cationic arginine-rich peptides (CARPs) as a novel class of mitochondria-targeted neuroprotective therapeutics [PDF]
, 2018 Stroke is the second leading cause of death globally and represents a major cause of devastating long-term disability. Despite sustained efforts to develop clinically effective neuroprotective therapies, presently there is no clinically available ...
Anderton, Ryan S +4 more
core +1 more source
Increased peripheral lipid clearance in an animal model of amyotrophic lateral sclerosis [PDF]
The Journal of Lipid Research 48, 7 (07/2007) 1571-1580, 2007 Amyotrophic lateral sclerosis (ALS) is the most common adult motor neuron disease, causing motor neuron degeneration, muscle atrophy, paralysis, and death. Despite this degenerative process, a stable hypermetabolic state has been observed in a large subset of patients.
arxiv +1 more source
Mechanisms of Neuroprotection by Quercetin: Counteracting Oxidative Stress and More
Oxidative Medicine and Cellular Longevity, 2016 Increasing interest has recently focused on determining whether several natural compounds, collectively referred to as nutraceuticals, may exert neuroprotective actions in the developing, adult, and aging nervous system.
L. Costa +3 more
semanticscholar +1 more source
Adult mesenchymal stem cell therapy for myelin repair in Multiple Sclerosis. [PDF]
, 2012 Multiple sclerosis (MS) is a demyelinating immune-mediated disease of the central nervous system (CNS). It is the most frequent neurological disease in young adults and affects over 2 million people worldwide.
Aigner, Ludwig, Rivera, Francisco J
core +2 more sources
Antioxidant Therapies for Neuroprotection—A Review
Journal of Clinical Medicine, 2019 Although moderate concentrations of reactive oxygen species (ROS) and reactive nitrogen species (RNS) are crucial for various physiological processes within the human body, their overproduction leads to oxidative stress, defined as the imbalance between ...
R. Teleanu +4 more
semanticscholar +1 more source
Imbalance of p75(NTR)/TrkB protein expression in Huntington's disease: Implication for neuroprotective therapies [PDF]
, 2013 Neuroprotective therapies based on brain-derived neurotrophic factor (BDNF) administration have been proposed for Huntington's disease (HD) treatment. However, our group has recently reported reduced levels of TrkB in HD mouse models and HD human brain ...
Alberch, J. +5 more
core +1 more source